Related Experiment Video
Updated: Jun 28, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
PTK6: An emerging biomarker for prognosis and immunotherapeutic response in clear cell renal carcinoma (KIRC)
Lizhen Lin1,2,3, Siming Gong3,4, Chao Deng3,4
1Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Abstract:
Kidney renal clear cell carcinoma (KIRC), one of the most prevalent form of kidney carcinoma, is highly aggressive cancer known for significant immune infiltration and high mortality rates. The absence of sensitivity to traditional therapy has spurred the search for new treatments. Protein Tyrosine Kinase 6 (PTK6) is implicated in promoting cancer growth, spread, and metastasis. Our review of The Cancer Genome Atlas database revealed PTK6 overexpression in KIRC, though its specific role in this cancer type was unclear. We investigated PTK6's cancer-promoting roles in KIRC using the database and confirmed our findings with patient-derived tissues. Our analysis showed that elevated PTK6 expression is linked to worse outcomes and higher levels of immune infiltration. It also correlates positively with neo-antigens (NEO) and DNA ploidy changes in KIRC. This research delves into PTK6's role in KIRC development, suggesting PTK6 as a possible biomarker for prognosis and treatment in KIRC.
Insights
Protein Tyrosine Kinase 6 (PTK6) is overexpressed in kidney renal clear cell carcinoma (KIRC), correlating with poor prognosis and increased immune infiltration. This suggests PTK6 as a potential biomarker for KIRC treatment strategies.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Pathology
Background:
- Kidney renal clear cell carcinoma (KIRC) is an aggressive cancer with high mortality.
- Limited sensitivity to conventional therapies necessitates novel treatment approaches.
- Protein Tyrosine Kinase 6 (PTK6) is recognized for its role in cancer progression and metastasis.
Purpose of the Study:
- To investigate the role of PTK6 in KIRC development and progression.
- To determine if PTK6 expression correlates with patient outcomes and immune characteristics in KIRC.
- To evaluate PTK6 as a potential prognostic biomarker for KIRC.
Main Methods:
- Analysis of The Cancer Genome Atlas (TCGA) database for PTK6 expression in KIRC.
- Validation of PTK6 expression using patient-derived KIRC tissues.
- Correlation analysis of PTK6 levels with clinical outcomes, immune infiltration, neo-antigens (NEO), and DNA ploidy.
Main Results:
- PTK6 was found to be overexpressed in KIRC.
- Elevated PTK6 expression is significantly associated with worse patient prognosis.
- Higher PTK6 levels correlate with increased immune infiltration, neo-antigens, and DNA ploidy alterations in KIRC.
Conclusions:
- PTK6 plays a significant role in promoting KIRC.
- PTK6 expression levels are linked to key indicators of tumor aggressiveness and immune response.
- PTK6 emerges as a promising biomarker for predicting prognosis and guiding therapeutic strategies in KIRC.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018